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Letter to the Editor
Management of hepatocellular adenoma
during pregnancy
Although the aetiology of hepatocellular adenoma
is unknown, these benign tumours seem to be re-
lated to the use of oral contraceptives (1). An as-
sociation with pregnancy has also been described,
probably due to increased levels of endogenous
steroid hormones (3, 4). During pregnancy the risk
of rupture of hepatocellular adenomas exists, and
this is associated with high foetal and maternal
mortality (3, 5–8). In non-pregnant women, surgi-
cal resection is often indicated in larger hepatocel-
lular adenomas because of a proven risk of rupture
(1, 2, 9) or malignant transformation (10). Success-
ful resection of malignant hepatic tumours during
gestation has been reported (11).
We report a case of a 32-year-old pregnant wo-
man with a hepatocellular adenoma, where surgi-
cal excision was performed. At 12 weeks’ gestation
the patient complained of increasing epigastric
pain. She had been taking oral contraceptives for
15 years and did not use either alcohol or hepato-
toxic medication. Except for an elevated alkaline
phosphatase level of 273 (n. 25–75) IU/L and a g-
glutamyl transpeptidase level of 72 (n. 5–35) IU/
L, all laboratory results were within normal limits
(including alpha-fetoprotein) and actual or past in-
fection with hepatitis B or C was excluded. Ultra-
sonography followed by computed tomography
demonstrated a 7¿9 cm tumour in the left hepatic
lobe, consistent with either hepatocellular aden-
oma or focal nodular hyperplasia. Subsequent
ultrasonography-guided percutaneous biopsy was
consistent with hepatocellular adenoma, but a
highly differentiated liver cell carcinoma could not
be excluded. Radiological, laboratory and histo-
logical findings, including the patient’s history of
oral contraceptive use during 15 years, made the
diagnosis of hepatocellular adenoma most likely.
Considering the risk of a rupture in case of a
hepatocellular adenoma, a resection of segment II
and III was performed at 13 weeks’ gestation. His-
tological study of the tumour revealed free surgical
margins of a hepatocellular adenoma in the left
liver lobe. The postoperative recovery was unre-
markable and the patient was discharged on the 7th
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postoperative day. There were no other problems
during her pregnancy and the delivery was un-
eventful. Mother and child were in good condition
12 months after surgery.
In the last 40 years an increasing incidence of
hepatocellular adenoma has been observed. In
women who have never used oral contraceptives,
hepatocellular adenoma develops at an annual rate
of approximately 0,012 per 10.000. On the other
hand, in women who have used oral contraceptives
for more than 9 years, the risk of developing a
hepatocellular adenoma is increased 25-fold (1).
The use of oral contraceptives not only increases
the risk of developing a hepatocellular adenoma,
but it also increases the risk of spontaneous rup-
ture (2). As a consequence, in patients who have
been advised to discontinue oral contraception, re-
gression of hepatocellular adenoma has been de-
scribed (12). However, persistent growth of the tu-
mour after cessation of oral contraception can oc-
cur as well (13).
Discussion about the management of hepatocel-
lular adenoma is still going on. Once the diagnosis
of hepatocellular adenoma has seen established, we
advise patients to discontinue oral contraception
and to avoid pregnancy. Asymptomatic tumours
with a diameter of less than 5 cm are treated con-
servatively, i.e. discontinuation of oral contracep-
tive use and ultrasonographic observation (14, 15).
Primary surgical resection is performed in case of
an initial diameter of 5 cm or more, or in patients
with serious complaints.
High levels of sex steroids and increased vascu-
larity of the liver during pregnancy increases the
chances of liver rupture (3). In a review by Bis et
al. comprising 91 cases, several cases of ruptured
hepatocellular adenoma with intraperitoneal hae-
morrhage during gestation have been described,
with a reported 59% maternal and 62% foetal mor-
tality (8). The reason for this high mortality rate
might be a serious delay in diagnosis because of
confusion with other diseases, like preeclampsia or
pulmonary embolism, which leads to a poor gen-
eral condition prior to surgery (3, 6).
Letter to the Editor
Because of the unpredictable behaviour of
hepatocellular adenomas and high maternal and
foetal mortality rates in case of a rupture during
pregnancy, we recommend resection once a large
(Ø5 cm) or a growing symptomatic hepatocellular
adenoma is diagnosed. When a surgical procedure
is performed during the second trimester, operat-
ive risks are minimal for both the mother and the
foetus (16).
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